Bookmark Article
Veteran pharmaceutical company AstraZeneca (NASDAQ: AZN) saw its shares rise over 3% on a typically down day for the market, largely due to a strong earnings report. The company reported nearly $15.2 billion in earnings for the third quarter, a 12% increase from the same period in 2024, with notable sales growth in oncology (up 16%) and respiratory and immunology (up 13%). The results contributed positively amid a 1.1% decline in the S&P 500 (SNPINDEX: ^GSPC).
Want More Context? 🔎
